The controversy over long-acting beta agonists: Examining the evidence

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 11, 2006, Pages 973-992

  Lang, David M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORDIL; FORMOTEROL; FORMOTEROL FUMARATE; ISOPRENALINE; LONG ACTING DRUG; NEDOCROMIL SODIUM; PLACEBO; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE;

AFRICAN AMERICAN; ARTICLE; ASTHMA; CAUSE OF DEATH; CHILDHOOD DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG FATALITY; DRUG LABELING; EVIDENCE BASED MEDICINE; FOLLOW UP; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INHALER; LENGTH OF STAY; META ANALYSIS; MONOTHERAPY; MORTALITY; PEAK EXPIRATORY FLOW; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREND STUDY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AFRICAN AMERICANS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; ETHANOLAMINES; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; UNITED STATES;

EID: 33751019468     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.11.973     Document Type: Article

References (67)

1. Aaronson D. The "black box" warning and allergy drugs. J Allergy Clin Immunol 2006; 117:40-44.
2. Nelson H, Weiss S, Bleecker E, Yancey S, Dorinsky P. The Salmeterol Multicenter Asthma Research Trial. Chest 2006; 129:15-26.
3. Critser G. Generation Rx: How Prescription Drugs Are Altering American Lives, Minds, and Bodies. Boston MA, Houghton-Mifflin, 2005
4. Topol E. Arthritis medicines and cardiovascular events - "house of coxibs." JAMA 2005; 293:366-368.
5. Beasley CRW, Pearce NE, Crane J. Worldwide trends in asthma mortality during the twentieth century. In: Lenfant C, Sheffer A, editors. Fatal Asthma. Lung Biology in Health and Disease Series. New York: Marcel Dekker, 1998:13-30.
6. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 1978; 7:319-338.
7. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand 1981-83: case-control study. Lancet 1989; 1:917-922.
8. Beasley R, Pearce N, Crane J, Burgess C. β-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol 1999; 103:S18-30.
9. McFadden ER, Warren EL. Observations on asthma mortality. Ann Intern Med 1997; 127:142-147.
10. Garrett J, Kolbe J, Richards G, Whitlock T, Rea H. Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand; what lessons have been learned? Thorax 1995; 50:303-311.
11. Mannino DM, Homa DM, Pertkowski CA, et al. Surveillance for asthma - United States, 1960-1995. MMWR 1998; 47:1-27.
12. Peat JK, van den Berg RH, Green WF, Mellis CM, Leeder SR, Woolcock AJ. Changing prevalence of asthma in Australian children. BMJ 1994; 308:1591-1596.
13. Haahtela T, Lindholm H, Bjorksten F, Koskenvuo K, Laitinen LA. Prevalence of asthma in Finnish young men. BMJ 1990; 301:266-268.
14. Ninan TK, Russell G. Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart. BMJ 1992; 304:873-875.
15. Asher MI, Pattemore PK, Harrison AC, Mitchell EA, Rea HH, Stewart AW. International comparison of the prevalence of bronchial hyper-responsiveness and asthma symptoms. Am Rev Respir Dis 1988; 138:524-529.
16. Sears MR, Jones DT, Holdaway MD. Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children. Thorax 1986; 41:283-291.
17. Fitzgerald JM. Sears MR, Roberts RS. Symptoms of asthma and airway hyperresponsiveness to methacholine in a population of Canadian schoolchildren. Am Rev Respir Dis 1988; 138:285.
18. Lang DM, Polansky M. Patterns of asthma mortality in Philadelphia: 1969-1991. N Engl J Med 1994; 331:1542-1547.
19. Carr W, Zeitel L, Weiss K. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health 1992; 82:59-65.
20. Grant EN, Lyttle CS, Weiss KB. The relation of socioeconomic factors and racial/ethnic differences in US asthma mortality. Am J Public Health 2000; 90:1923-1925.
21. Lang DM. 2001: The asthma odyssey. Ann Allergy Asthma Immunol 2001; 87:91-95.
22. Wilson JW, Jenkins CR. Asthma mortality: where is it going? Med J Aust 1996; 164:391-393.
23. Campbell MJ, Cogman GR. Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. Br Med J 1997; 314:1439-1441.
24. Goldman M. Rachmiel M. Gendler I, Katz Y. Decrease in asthma mortality rate in Israel from 1991-1995: is it related to increased use of inhaled corticosteroids? J Allergy Clin Immunol 2000; 105:71-74.
25. Data obtained from www.cdc.gov. Accessed October 16, 2006.
26. Suissa S, Ernst P, Benayoun S. Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336.
27. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268:3462-3464.
28. O'Byrne P. Pharmacologic interventions to reduce the risk of asthma exacerbations. Proc Am Thorac Soc 2004; 1:105-108.
29. Pauwells RA, Lofdahl C, Postma DS. O'Byrne P. Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411.
30. O'Byrne P, Barnes P, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA Randomized Trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
31. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-224.
32. Woolcock A, Lundback B, Ringdal N. Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996, 153:1481-1488.
33. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170:836-844.
34. Walters EH, Walters JAE, Gibson MDP. Long-acting beta2-agonists for stable chronic asthma. Cochrane Database Syst Rev 2003, Issue 3. Art. No. CD001385. DOI: 10.1002/14651858.CD001385.
35. Shrewsbury S. Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373.
36. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroid in symptomatic asthma. Thorax 2005; 60:730-734.
37. Sin DD, Man J, Sharpe H, Gan WQ, Man SFP. Pharmacological management to reduce exacerbations in adults with asthma. A systematic review and meta-analysis. JAMA 2004, 292:367-376.
38. Lundback B, Jenkins C, Price MJ, Thwaites RM. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microgram twice daily and budesonide 800 microgram twice daily in the treatment of adults and adolescents with asthma. Respir Med 2000; 94:724-732.
39. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49:247-250.
40. Lanes S, Lanza L, Wentworth C. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998; 158:857-861.
41. Meier CR, Jick H. Drug use and pulmonary death rates in increasing symptomatic asthma patients in the UK. Thorax 1997; 52:612-617.
42. Williams C, Crossland L, Finnerty J, et al. A case control study of salmeterol and near fatal attacks of asthma. Thorax 1998; 53:7-13.
43. Lanes S, Garcia Rodriguez LA, Herta C. Respiratory medications and risk of asthma death. Thorax 2002; 57:683-686.
44. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case control study. Br Med J 2005; 330:117-124.
45. Expert Panel Report: Guidelines for the diagnosis and management of asthma. Update on Selected Topics - 2002. J Allergy Clin Immunol 2002; 110:S141-S207.
46. Jenkins C, Woolcock AJ, Saarelainin P, Lundback B, James MH. Salmeterol/ fluticasone propionate combination therapy 50/250 micrograms twice daily is more effective than budesonide 800 micrograms twice daily in treating moderate to severe asthma. Respir Med 2000; 94:715-723.
47. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037.
48. Johnson M. Molecular mechanisms of β2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117:18-24.
49. Wechsler M, Israel E. How pharmacogenetics will play a role in the management of asthma. Am J Respir Crit Care Med 2005; 172:12-18.
50. Wechsler M, Lehman E, Lazarus S, et al. β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
51. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta 2 adrenoceptor polymorphism. Thorax 2000; 55:762-767.
52. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. A randomized controlled trial. JAMA 2001; 285:2583-2593.
53. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. US Department of Health and Human Services. Publication No. 97-4052; 1997.
54. Mak H, Johnston P, Abbey H, Talamo RC. Prevalence of asthma and health service utilization of asthmatic children in an inner city. J Allergy Clin Immunol 1982; 70:367-372.
55. Coultas DB, Gong H, Grad R, et al. Respiratory diseases in minorities in the United States. Am J Respir Crit Care Med 1994, 149:S93-S131.
56. Lozano P, Connell FA, Koepsell TD. Use of health services by African-American children with asthma on Medicaid. JAMA 1995; 274:469-473.
57. Zoratti EM, Havstad S, Rodriguez J, Robens-Paradise Y, Lafata JE, McCarthy BD. Health care service use by African-Americans and Caucasians with asthma in a managed care setting. Am J Respir Crit Care Med 1998; 158:371-377.
58. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74.
59. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med 2005; 353:2637-2639.
60. Wolfe J, LaForce C, Friedman B, et al. Formoterol 24 μg bid, and serious asthma exacerbations. Chest 2006; 129:27-38.
61. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912.
62. Bensch G, Berger W, Blokhin GM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002; 89:180-190.
63. Grady D. Experts to consider withdrawal of asthma drugs. New York Times, 7/13/05.
64. Nelson H, Busse W, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088-1095.
65. Busse W, Nelson H. Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075-1080.
66. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomized, comparative trial. BMJ 2003; 327:891.
67. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005; CD003137.